Talphera, Inc. (TLPH) Stock

Talphera, Inc. operates as a specialized pharmaceutical firm dedicated to advancing therapies tailored for use in closely monitored medical environments. At the forefront of its development pipeline is Niyad, a lyophilized formulation of nafamostat currently undergoing investigation under an investigational device exemption. Designed as an anticoagulant for extracorporeal circuits, Niyad represents a pivotal innovation aimed at enhancing treatment protocols in critical care settings.

Originally established as AcelRx Pharmaceuticals, Inc. and rebranded as Talphera, Inc. in January 2024, the company has a robust portfolio extending beyond Niyad. One notable project is LTX-608, a promising candidate with anti-inflammatory and antiviral properties intended for conditions such as disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Talphera also focuses on therapeutic solutions like Fedsyra, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe, addressing critical medical needs with innovative pharmaceutical formulations.

Headquartered in San Mateo, California, Talphera, Inc. leverages its extensive expertise in pharmaceutical research and development to drive forward transformative healthcare solutions. By prioritizing precision and efficacy in its product innovations, the company remains committed to advancing patient care standards and meeting the evolving demands of medically supervised treatment environments globally.